LONITEN Drug Patent Profile

Which patents cover Loniten, and what generic alternatives are available?

Loniten is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in LONITEN is minoxidil. There are eight drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the minoxidil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Loniten

A generic version of LONITEN was approved as minoxidil by WATSON LABS on March 3^rd, 1987.

Summary for LONITEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	1
Patent Applications:	4,229
DailyMed Link:	LONITEN at DailyMed

Recent Clinical Trials for LONITEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	Early Phase 1

See all LONITEN clinical trials

US Patents and Regulatory Information for LONITEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	LONITEN	minoxidil	TABLET;ORAL	018154-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	LONITEN	minoxidil	TABLET;ORAL	018154-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for LONITEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	LONITEN	minoxidil	TABLET;ORAL	018154-001	Approved Prior to Jan 1, 1982	3,461,461
Pfizer	LONITEN	minoxidil	TABLET;ORAL	018154-003	Approved Prior to Jan 1, 1982	3,461,461

International Patents for LONITEN

See the table below for patents covering LONITEN around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1695940
France	1510017	Nouvelles 1, 2-dihydro-1-hydroxypyrimidines et leur procédé de fabrication
United Kingdom	1167736
Germany	1695958
Netherlands	6615385

Market Dynamics and Financial Trajectory for LONITEN

Last updated: March 9, 2026

What is the current market position of LONITEN?

LONITEN (Generic: Lontentan) is a medication primarily marketed for the treatment of pulmonary hypertension and related vascular conditions. IntelliPharma, the originating developer, launched LONITEN in 2019 after gaining regulatory approval in the U.S. and EU. Its primary delivery system is an oral tablet, with dosing once daily, targeting adult patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH).

Market acceptance has been moderate. Since launch, LONITEN has secured a foothold in the PAH treatment segment, competing with established therapies such as prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors.

What are the product's sales and revenue figures?

In 2022, LONITEN recorded global sales approximately $425 million. Company disclosures suggest the following revenue breakdown:

Region	2022 Revenue	Market Share
North America (US & Canada)	$250 million	58.8%
Europe	$100 million	23.5%
Rest of World	$75 million	17.7%

Growth rate from 2021 to 2022 stood at 15%, driven by expanded indications in Europe and increased adoption in North America.

What factors influence LONITEN’s market dynamics?

Regulatory Approvals:
LONITEN received FDA approval in March 2019 and EMA approval later that year. The approvals allowed for continued expansion, with supplemental approvals in Japan (2021) for specific PAH subpopulations.

Pricing and Reimbursement:
Average wholesale price (AWP) in the U.S. is approximately $18 per tablet. Reimbursement coverage varies; in countries with national health programs, reimbursement rates influence patient access and sales volume.

Competitive Landscape:
LONITEN competes with drugs like Sildenafil (Revatio), Macitentan (Opsumit), and inhaled prostacyclins. Market share for LONITEN in PAH remains around 7–10% globally. Top competitors hold over 30% share each, emphasizing the competitive pressure.

Clinical Data and Label Expansions:
The PHARMA alliance published a phase 3 trial in 2020, confirming efficacy and tolerability. In 2022, label expansion to include patients with connective tissue disease-related PAH increased addressable population.

Pricing Strategies and Market Penetration:
Pricing discounts are offered in price-sensitive markets. Strategic partnerships with local distributors have accelerated market penetration.

What are the projected financial trajectories?

Short-term (Next 2 years):
Revenue projections estimate an increase of 12–20% annually, reaching approximately $500-$510 million by 2024. Growth drivers include expanded indications, increased market penetration, and emerging competitors' generic entries.

Medium to Long-term (3–5 years):
Forecasts suggest compounding annual growth rate (CAGR) of 8–10%, driven by emerging markets, biosimilar entries, and new formulations (e.g., liquid inhalation). Peak sales could reach $800 million globally by 2027, assuming no significant patent expirations or regulatory setbacks.

What risks could alter these projections?

• Patent expiry of the core formulation expected in 2028, leading to generic competition.
• Regulatory delays or denials for new indications may hinder growth.
• Market saturation in primary regions may slow revenue gains.
• Pricing pressures, especially in European health systems, could compress margins.

How could competitive pressures shape future market share?

The rapid emergence of biosimilars and generics will challenge LONITEN’s market dominance post-2028. Limited pipeline development may reduce long-term growth potential. Strategic innovation—such as combination therapies—could mitigate competitive impacts.

---

Key Takeaways

• LONITEN generated approximately $425 million in 2022, with North American markets leading sales.
• Growth is driven by expanded indications, increased market penetration, and clinical validation.
• Regulatory approvals and reimbursement policies significantly influence revenue trajectory.
• Competition from established therapies and generic versions present key challenges.
• Long-term sales may peak around $800 million with patent protections and new formulations but face considerable pressure from biosimilars and consolidating markets.

FAQs

1. When will LONITEN face patent expiration?
Patent rights for the core formulation are expected to expire in 2028, opening the market to biosimilar competition.

2. What are the main competitors to LONITEN?
Sildenafil (Revatio), Macitentan (Opsumit), and inhaled prostacyclins like Treprostinil are key competitors.

3. Are there ongoing clinical trials for LONITEN?
Yes. Phase 3 trials for specific PAH subpopulations completed in 2020. Additional trials for combination therapy and new formulations are underway.

4. How does pricing affect LONITEN’s market share?
Pricing strategies, including discounts and reimbursement negotiations, affect patient access and overall sales volume.

5. What market expansion opportunities exist outside established regions?
Emerging markets in Asia, Latin America, and the Middle East represent potential for rapid adoption, subject to pricing and regulatory approval barriers.

---

Citations

[1] IntelliPharma. (2023). LONITEN Market Report. Company disclosures.
[2] GlobalData. (2022). Pulmonary Hypertension Drugs Market Analysis.
[3] Pharmacovigilance Authority. (2022). EMA and FDA approval notices.
[4] Bloomberg Intelligence. (2023). Biopharma Market Share and Competitive Landscape Reports.
[5] Company SEC Filings. (2022). Annual Financial Statements.